Amarin Corporation plc
AMRN•NASDAQ•Healthcare•Drug Manufacturers - General

About Amarin Corporation

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websitewww.amarincorp.com
Phone353 0 166 99020
Address
One Central Plaza, 5th Floor Dublin, D02 K7K5 Ireland

Corporate Identifiers

CIK0000897448
CUSIP023111404
ISINUS0231114044
SIC2834

Leadership Team & Key Executives

Aaron D. Berg
Chief Executive Officer, President and Director
Peter L. Fishman
Senior Vice President and Chief Financial Officer
Dr. Steven B. Ketchum Ph.D.
Executive Vice President, President of Research and Development and Chief Scientific Officer
Jonathan N. Provoost
Executive Vice President, Chief Legal and Compliance Officer and Secretary
Dr. David Keenan Ph.D.
Executive Vice President and Chief Operating Officer
Eric Boothe
Senior Vice President of Corporate Development